Sonoma Pharmaceuticals Reports 2026 Fiscal Year Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Source: seekingalpha
- Quarterly Performance Review: Sonoma Pharmaceuticals reported a Q4 GAAP EPS of -$0.33, with revenue reaching $5.56 million, a 48.3% year-over-year increase, indicating signs of recovery in the market.
- Annual Revenue Growth: Total revenues for fiscal year 2026 were $19.5 million, up $5.2 million from $14.3 million in fiscal year 2025, demonstrating significant progress in sales and market expansion.
- Net Loss Improvement: The net loss for fiscal year 2026 was $3.2 million, a decrease of $0.3 million or 8% compared to the same period last year, reflecting improvements in cost control and operational efficiency.
- EBITDA Loss Reduction: The EBITDA loss for fiscal year 2026 was $2.1 million, down $1.2 million or 38% from the $3.3 million loss in the previous year, indicating a positive trend in the company's recovery of profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNOA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNOA
About SNOA
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sonoma Pharmaceuticals Receives FDA Clearance for Expanded Microdacyn Wound Solution
- FDA Clearance: Sonoma Pharmaceuticals has received a new 510(k) clearance from the FDA for its Microdacyn® Wound Irrigation Solution, expanding its use to various wound types, including pressure ulcers and diabetic foot ulcers, thereby enhancing its competitive edge in the healthcare market.
- Multiple Use Labeling: The new clearance allows Microdacyn to be used multiple times for a single patient, increasing product flexibility and market appeal, which is expected to attract more commercial partners and distributors.
- Packaging Innovation: The new product packaging includes 4 oz, 8 oz, 16 oz, and 34 oz PET bottles with polypropylene flip-top caps, catering to diverse market needs and enhancing product adaptability in the market.
- Strategic Investment Commitment: CEO Amy Trombly stated that this FDA clearance reflects the company's commitment to regulatory investment, aiming to support long-term growth strategies by broadening product lines and market opportunities.
See More
Sonoma Pharmaceuticals Receives FDA Clearance for Expanded Microdacyn Wound Solution
- FDA Clearance: Sonoma Pharmaceuticals has received a new 510(k) clearance from the FDA, expanding the Microdacyn® Wound Irrigation Solution's applications, including multiple-use labeling and new packaging configurations, enhancing its market competitiveness.
- Expanded Applications: The new clearance allows for use under healthcare professional supervision for various wound types, including diabetic foot ulcers and post-surgical wounds, which is expected to significantly boost market demand and sales potential.
- Packaging Innovation: New packaging options include 4 oz, 8 oz, 16 oz, and 34 oz PET bottles, increasing product usability and market appeal, likely attracting more distributors and private-label customers.
- Strategic Growth Commitment: CEO Amy Trombly stated that this FDA clearance reflects Sonoma's commitment to regulatory investment, aiming to drive long-term growth strategies by broadening product claims and market opportunities.
See More
Sonoma Pharmaceuticals Reports 2026 Fiscal Year Growth
- Quarterly Performance Review: Sonoma Pharmaceuticals reported a Q4 GAAP EPS of -$0.33, with revenue reaching $5.56 million, a 48.3% year-over-year increase, indicating signs of recovery in the market.
- Annual Revenue Growth: Total revenues for fiscal year 2026 were $19.5 million, up $5.2 million from $14.3 million in fiscal year 2025, demonstrating significant progress in sales and market expansion.
- Net Loss Improvement: The net loss for fiscal year 2026 was $3.2 million, a decrease of $0.3 million or 8% compared to the same period last year, reflecting improvements in cost control and operational efficiency.
- EBITDA Loss Reduction: The EBITDA loss for fiscal year 2026 was $2.1 million, down $1.2 million or 38% from the $3.3 million loss in the previous year, indicating a positive trend in the company's recovery of profitability.
See More
Sonoma Pharmaceuticals Completes $4 Million Offering
- Offering Size: Sonoma Pharmaceuticals priced a $4 million offering of 2.96 million shares and 2.96 million warrants at $1.35 per share, with proceeds aimed at general corporate purposes, including working capital.
- Over-Allotment Option: The company granted Dawson James Securities a 45-day option to purchase up to 15% of the shares or warrants sold in the offering to cover any over-allotments, enhancing financial flexibility.
- Market Performance: Over the past year, SNOA's stock has traded between $0.85 and $6.92, closing at $1.14, down 36.67%, indicating market concerns regarding the company's outlook.
- Product Applications: Sonoma Pharma focuses on developing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants, showcasing its product diversity and market potential.
See More
Sonoma Pharmaceuticals Reports Q3 Earnings
- Earnings Report: Sonoma Pharmaceuticals reported a Q3 GAAP EPS of -$0.48, indicating challenges in profitability that could affect investor confidence.
- Revenue Performance: The company generated $4.3 million in revenue, which, while showing some sales, may fall short of market expectations, reflecting volatility in product demand.
- Market Reaction: Ongoing losses and revenue underperformance may lead investors to adopt a cautious stance on Sonoma's future growth prospects, putting pressure on the stock price.
- Strategic Adjustments: The company may need to reassess its market strategies and product lines to address current financial challenges and seek pathways to improve profitability.
See More
5 Healthcare Stocks Soaring This Week
Top Performing Healthcare Stocks: Five healthcare stocks, including Sonoma Pharmaceuticals, Evoke Pharma, KALA Bio, Ginkgo Bioworks, and Soligenix, have shown significant week-on-week momentum gains, indicating potential breakout opportunities in the sector.
Sonoma Pharmaceuticals Highlights: Leading the pack, Sonoma Pharmaceuticals experienced a remarkable 66.73-point momentum score increase, driven by its focus on antimicrobial and dermatology products, with a 44.60% surge over the last month.
Evoke Pharma and KALA Bio Performance: Evoke Pharma's momentum score rose significantly due to its gastrointestinal treatment product, while KALA Bio saw a strong increase linked to therapies for rare ocular diseases, both showing impressive price trends.
Market Context and Momentum Ranking: The Benzinga Edge Rankings report highlights that these stocks' dramatic momentum gains reflect strong price performance and volatility, despite broader market declines in major ETFs like SPY and QQQ.
See More
Sonoma Pharmaceuticals Receives FDA Clearance for Expanded Microdacyn Wound Solution
- FDA Clearance: Sonoma Pharmaceuticals has received a new 510(k) clearance from the FDA for its Microdacyn® Wound Irrigation Solution, expanding its use to various wound types, including pressure ulcers and diabetic foot ulcers, thereby enhancing its competitive edge in the healthcare market.
- Multiple Use Labeling: The new clearance allows Microdacyn to be used multiple times for a single patient, increasing product flexibility and market appeal, which is expected to attract more commercial partners and distributors.
- Packaging Innovation: The new product packaging includes 4 oz, 8 oz, 16 oz, and 34 oz PET bottles with polypropylene flip-top caps, catering to diverse market needs and enhancing product adaptability in the market.
- Strategic Investment Commitment: CEO Amy Trombly stated that this FDA clearance reflects the company's commitment to regulatory investment, aiming to support long-term growth strategies by broadening product lines and market opportunities.
See More
Sonoma Pharmaceuticals Receives FDA Clearance for Expanded Microdacyn Wound Solution
- FDA Clearance: Sonoma Pharmaceuticals has received a new 510(k) clearance from the FDA, expanding the Microdacyn® Wound Irrigation Solution's applications, including multiple-use labeling and new packaging configurations, enhancing its market competitiveness.
- Expanded Applications: The new clearance allows for use under healthcare professional supervision for various wound types, including diabetic foot ulcers and post-surgical wounds, which is expected to significantly boost market demand and sales potential.
- Packaging Innovation: New packaging options include 4 oz, 8 oz, 16 oz, and 34 oz PET bottles, increasing product usability and market appeal, likely attracting more distributors and private-label customers.
- Strategic Growth Commitment: CEO Amy Trombly stated that this FDA clearance reflects Sonoma's commitment to regulatory investment, aiming to drive long-term growth strategies by broadening product claims and market opportunities.
See More
Sonoma Pharmaceuticals Reports 2026 Fiscal Year Growth
- Quarterly Performance Review: Sonoma Pharmaceuticals reported a Q4 GAAP EPS of -$0.33, with revenue reaching $5.56 million, a 48.3% year-over-year increase, indicating signs of recovery in the market.
- Annual Revenue Growth: Total revenues for fiscal year 2026 were $19.5 million, up $5.2 million from $14.3 million in fiscal year 2025, demonstrating significant progress in sales and market expansion.
- Net Loss Improvement: The net loss for fiscal year 2026 was $3.2 million, a decrease of $0.3 million or 8% compared to the same period last year, reflecting improvements in cost control and operational efficiency.
- EBITDA Loss Reduction: The EBITDA loss for fiscal year 2026 was $2.1 million, down $1.2 million or 38% from the $3.3 million loss in the previous year, indicating a positive trend in the company's recovery of profitability.
See More
Sonoma Pharmaceuticals Completes $4 Million Offering
- Offering Size: Sonoma Pharmaceuticals priced a $4 million offering of 2.96 million shares and 2.96 million warrants at $1.35 per share, with proceeds aimed at general corporate purposes, including working capital.
- Over-Allotment Option: The company granted Dawson James Securities a 45-day option to purchase up to 15% of the shares or warrants sold in the offering to cover any over-allotments, enhancing financial flexibility.
- Market Performance: Over the past year, SNOA's stock has traded between $0.85 and $6.92, closing at $1.14, down 36.67%, indicating market concerns regarding the company's outlook.
- Product Applications: Sonoma Pharma focuses on developing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants, showcasing its product diversity and market potential.
See More
Sonoma Pharmaceuticals Reports Q3 Earnings
- Earnings Report: Sonoma Pharmaceuticals reported a Q3 GAAP EPS of -$0.48, indicating challenges in profitability that could affect investor confidence.
- Revenue Performance: The company generated $4.3 million in revenue, which, while showing some sales, may fall short of market expectations, reflecting volatility in product demand.
- Market Reaction: Ongoing losses and revenue underperformance may lead investors to adopt a cautious stance on Sonoma's future growth prospects, putting pressure on the stock price.
- Strategic Adjustments: The company may need to reassess its market strategies and product lines to address current financial challenges and seek pathways to improve profitability.
See More
5 Healthcare Stocks Soaring This Week
Top Performing Healthcare Stocks: Five healthcare stocks, including Sonoma Pharmaceuticals, Evoke Pharma, KALA Bio, Ginkgo Bioworks, and Soligenix, have shown significant week-on-week momentum gains, indicating potential breakout opportunities in the sector.
Sonoma Pharmaceuticals Highlights: Leading the pack, Sonoma Pharmaceuticals experienced a remarkable 66.73-point momentum score increase, driven by its focus on antimicrobial and dermatology products, with a 44.60% surge over the last month.
Evoke Pharma and KALA Bio Performance: Evoke Pharma's momentum score rose significantly due to its gastrointestinal treatment product, while KALA Bio saw a strong increase linked to therapies for rare ocular diseases, both showing impressive price trends.
Market Context and Momentum Ranking: The Benzinga Edge Rankings report highlights that these stocks' dramatic momentum gains reflect strong price performance and volatility, despite broader market declines in major ETFs like SPY and QQQ.
See More
